Dr. Dixit is a Physician Executive with more than 20 years of experience in the healthcare and life sciences industry. She has been in executive leadership at Sanofi, Allergan, and GE and has been responsible for launching a number of innovative medicines. She was voted innovator of the year at GE in 2008, nominated as a Top 50 Thought Leader in “Big Data” in Life Sciences in 2016, and featured in the Pharma Executive Magazine cover-page article “Real-World Evidence: From Volume to Value” (Oct 13, 2016). Shailja has built and has had successful exits with many projects.Sidhartha Shankar
Sidhartha has more than 20 years of Technology Management experience. Most recently, he was CTO of Ediom, LLC, an AI/ Big Data startup focused on building data products for the provider market in a JV with Vizient, the largest GPO in USA. Prior to that, he was Managing Partner of iMedInvestments LLP, a cross-border advisory investment banking firm, and also VP of IT for Walkingspree Inc.- a specialty wellness provider. Sidhartha is a graduate of the Wharton Business School and the University of Pennsylvania and also a Software Engineering degree from NIT, India.Anne Whitaker
Anne is a seasoned healthcare executive with more than 28 years of experience across multiple companies and geographies. She has a proven track record of building and leading high-performance teams to successfully commercialize pharmaceuticals, consumer products and medical devices. Anne has been recognized in the pharmaceutical industry by Fierce Pharma as one of the top 25 Most Influential People in BioPharma in 2012 and 2013, and in 2014 as one of the top 25 Most Influential Women in BioPharma. She was recently recognized by PharmaVoice as one of the Top 100 most Inspiring Leaders in Healthcare and by Women, Inc. as one of the most Influential Corporate Directors in 2019. She is a member of Women Corporate Directors, Healthcare Businesswomen’s Association, International Women’s Forum and OnBoardNC. Anne is the current Chairman of Aerami Therapeutics, She serves as an independent director on the board of Cree, Mallinckrodt, and UDG Healthcare. She also serves on the Board of Trustees for the Univ. of North Alabama, her alma mater. She is an active industry advisor to private equity and venture capital funds in the US and Europe. Anne served as the President of the North America Region Head where she led team to deliver ~$10B in net sales equaling > 30% of the net sales. Anne served as the CEO and President of Synta Pharmaceuticals, in 2014 and 2015. She joined Bausch Health as an Ex. VP and Company Group Chairman for the Branded Pharmaceuticals segment in mid-2015. Later she served as the CEO and President of Novoclem Therapeutics, Inc. Anne holds a Bachelor of Science degree in chemistry from the University of North Alabama.Jean-Pierre Lehner
Jean-Pierre LEHNER MD, cardiologist and internal medicine graduate served the pharmaceutical industry for 30 years. Before joining pharmaceutical industry Jean-Pierre was practitioner in Hospital Bichat, Paris (France), where during the last 4 years he was heading the Intensive Care Unit of Cardiology.
Dr. Lehner assumed various roles in medical affairs. In 1981, he joined Roussel-Uclaf Company first as medical director in France, then in charge of international clinical development untill1992. Dr. Lehner served successively at Sanofi as Head of Clinical Development for 4 years before taking the scientific director position in France until 2002 and developed the European medical team before taking the position of Global Medical Director in 2005.
In 2009 Dr. Lehner was appointed as Senior Vice President & Chief Medical Officer reporting to the Head of R&D and to Sanofi’s CEO. In this position Jean-Pierre had responsibility for world-wide medical affairs, regulatory affairs, safety and HEOR research including comparative effectiveness. During these years Jean-Pierre had acquired à very large expertise in the benefit-risk assessment of marketed and non-marketed products and defended many regulatory files in front of the Global agencies.
Well-respected in the medical community & pharmaceutical industry, Dr. Lehner led the development of new concepts within Medical affairs to fit the external evolution such as Innovative methodologies for Real world research and development of Relative Medical Value to enhance the patient – centric value of drug development and played key role in enhancement of coverage and reimbursement dossier development.
He is now Executive Director of his own company (JPLPHARMA CONSULTING).